Lung Cancer Liquid Biopsy Global Market Report 2025
상품코드:1769646
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
폐암 액체 생검 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 예측 기간 동안의 성장은 폐암 발병률의 증가, 비침습적 진단 방법에 대한 수요 증가, 맞춤형 의약품의 채택 확대, 암 조기 발견에 대한 인식 제고, 암에 취약한 고령 인구의 증가에 기인할 수 있습니다. 이 기간 동안 예상되는 주요 동향으로는 순환 종양 DNA(ctDNA) 분석 기술의 발전, 엑소좀 기반 액체 생검 기술의 발전, 순환 종양 세포를 분리하기 위한 미세 유체 기술의 혁신, 바이오마커 해석을 위한 AI 및 머신 러닝의 통합, 다중 바이오마커 분석을 가능하게 하는 기술적 혁신 등이 있습니다.
폐암 발병률의 증가는 향후 몇 년 동안 폐암 액체 생검 시장의 성장을 촉진할 것으로 예상됩니다. 폐암은 폐에서 비정상적인 세포가 통제되지 않고 증식하는 질환으로, 일반적으로 흡연 및 환경 노출과 관련이 있습니다. 사례가 증가하는 주된 원인은 비정상적인 세포 성장을 유발하는 발암 물질에 폐를 노출시키는 흡연의 지속입니다. 폐암을 위한 액체 생검은 간단한 혈액 샘플을 통해 암 관련 유전적 변이와 종양 DNA를 검출할 수 있어 조기 진단, 개인 맞춤형 치료 선택, 질병 진행 또는 치료 반응의 지속적인 모니터링을 가능하게 합니다.
폐암 액체 생검 시장 주요 기업들은 조기 진단 개선, 진단 정확도 향상, 종양 진행 및 치료 반응의 비침습적 실시간 모니터링을 위해 혈액 기반 폐암 검진 테스트 개발 등 기술 혁신을 최우선 과제로 삼고 있습니다. 이러한 혈액 기반 검진 테스트는 혈액 내 바이오마커를 분석해 폐암을 초기 단계에서 탐지하며, 전통적인 방법에 비해 덜 침습적인 대안을 제공합니다. 예를 들어, 2023년 10월 미국 바이오기술 기업 DELFI Diagnostics Inc.는 조기 폐암 검출을 목표로 한 혈액 기반 액체 생검 검사인 FirstLook Lung을 출시했습니다. 이 검사는 fragmentomics 기술을 활용해 높은 민감도와 99.8%의 음성 예측 값으로 초기 단계의 폐암을 식별합니다. 이 검사는 위험군을 대상으로 접근성과 편의성이 뛰어난 초기 스크리닝 도구로 설계되었으며, 조기 검출률 향상, 스크리닝 참여율 증대, 가장 혜택을 볼 가능성이 높은 환자에게 영상 검사 자원을 우선적으로 할당하는 것을 목표로 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 폐암 액체 생검 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 폐암 액체 생검 시장 : 성장률 분석
세계의 폐암 액체 생검 시장 실적 : 규모와 성장(2019-2024년)
세계의 폐암 액체 생검 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 폐암 액체 생검 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 폐암 액체 생검 시장 : 제품별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
장치
소모품 키트 및 시약
소프트웨어 및 서비스
세계의 폐암 액체 생검 시장 : 기술별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
다중 유전자 병렬 분석(NGS)
단일 유전자 분석(PCR 마이크로어레이)
세계의 폐암 액체 생검 시장 : 바이오마커별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
유리 데옥시리보 핵산
순환 종양 데옥시리보 핵산
세포외 소포
순환 종양 세포
기타 바이오마커
세계의 폐암 액체 생검 시장 : 임상 응용에 의한 분석과 예측(2019-2024년, 2024-2029년, 2034년)
치료법의 선택
치료 모니터링
조기 암 검진
재발 모니터링
기타 용도
세계의 폐암 액체 생검 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
진단 및 화상 진단센터
병원
학술연구센터
기타 최종 사용자
세계의 폐암 액체 생검 시장 : 장치 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
PCR 장치
마이크로어레이 장치
차세대 시퀀싱(NGS) 장치
세계의 폐암 액체 생검 시장 : 소모품 키트 및 시약 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
샘플 채취 키트
증폭 시약
시퀀싱 시약
세계의 폐암 액체 생검 시장 : 소프트웨어 및 서비스 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
데이터 분석 소프트웨어
클라우드 기반 서비스
바이오인포매틱스 툴
제7장 지역별, 국가별 분석
세계의 폐암 액체 생검 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 폐암 액체 생검 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
폐암 액체 생검 시장 : 경쟁 구도
폐암 액체 생검 시장 : 기업 프로파일
F. Hoffmann-La Roche Ltd : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Biocept Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Agilent Technologies Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Eurofins Scientific : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Illumina Inc.
Sysmex Corporation
Bio-Rad Laboratories Inc.
QIAGEN NV
Exact Sciences Corp
Natera Inc.
Myriad Genetics Inc.
NeoGenomics Laboratories Inc.
Guardant Health Inc.
MDxHealth SA
Exosome Diagnostics Inc.
Menarini Silicon Biosystems SpA
Inivata Ltd
Lucence Diagnostics Pte Ltd
LungLife AI Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
폐암 액체 생검 시장(2029년) : 새로운 기회를 제공하는 국가
폐암 액체 생검 시장(2029년) : 새로운 기회를 제공하는 부문
폐암 액체 생검 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Lung cancer liquid biopsy is a non-invasive method that examines blood or other bodily fluids to identify tumor-derived genetic material or cells. This technique supports early detection, genetic profiling, and monitoring of lung cancer by capturing cancer-specific biomarkers, providing an alternative to traditional surgical tissue biopsies.
Lung cancer liquid biopsy products include instruments, consumables kits and reagents, and software and services. Instruments refer to the hardware and analytical tools used to process and evaluate liquid biopsy samples. The technology applied includes multi-gene parallel analysis methods such as next-generation sequencing (NGS) and single-gene techniques like PCR and microarrays. Biomarkers analyzed include cell-free DNA, circulating tumor DNA, extracellular vesicles, circulating tumor cells, and other related indicators. These biomarkers are utilized for various purposes, including therapy selection, treatment monitoring, early cancer detection, recurrence surveillance, and other clinical applications. End-users include diagnostic and imaging centers, hospitals, academic and research institutions, and other relevant facilities.
The lung cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides lung cancer liquid biopsy market statistics, including the lung cancer liquid biopsy industry's global market size, regional shares, competitors with the lung cancer liquid biopsy market share, detailed lung cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer liquid biopsy market. This lung cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The lung cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.95 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. Growth during the historic period can be attributed to the increasing prevalence of smoking- and pollution-related lung disorders, expanded use of liquid biopsy for treatment monitoring, growing investment in oncology research and development, rising demand for rapid and cost-effective diagnostic solutions, and an increasing number of clinical trials.
The lung cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. Growth in the forecast period can be attributed to the rising incidence of lung cancer, increasing demand for non-invasive diagnostic methods, growing adoption of personalized medicine, heightened awareness of early cancer detection, and a rising geriatric population more vulnerable to cancer. Key trends expected during this period include advancements in circulating tumor DNA (ctDNA) analysis technologies, progress in exosome-based liquid biopsy techniques, innovations in microfluidics for isolating circulating tumor cells, the integration of AI and machine learning for biomarker interpretation, and technological breakthroughs enabling multiplex biomarker analysis.
The rising incidence of lung cancer is expected to drive the growth of the lung cancer liquid biopsy market in the coming years. Lung cancer is a condition marked by the uncontrolled proliferation of abnormal cells in the lungs, commonly linked to smoking and environmental exposures. The increasing number of cases is primarily attributed to continued tobacco use, which exposes the lungs to carcinogens that initiate abnormal cell growth. Liquid biopsy for lung cancer enables the detection of cancer-related genetic mutations and tumor DNA through a simple blood sample, facilitating early diagnosis, personalized treatment selection, and ongoing monitoring of disease progression or therapeutic response. For example, in 2023, the American Cancer Society reported that as of January 1, 2022, 654,620 individuals in the U.S. had a history of lung cancer, with many living with metastatic disease. Approximately 80% of these patients were aged 65 or older, and 55% had been diagnosed within the past five years, reflecting low survival rates. Consequently, the growing incidence of lung cancer is significantly contributing to the expansion of the lung cancer liquid biopsy market.
Major companies in the lung cancer liquid biopsy market are prioritizing technological advancements, such as the development of blood-based lung cancer screening tests, to improve early detection, enhance diagnostic accuracy, and provide non-invasive, real-time monitoring of tumor progression and treatment response. These blood-based screening tests analyze biomarkers in the bloodstream to detect lung cancer at an early stage, offering a less invasive alternative to traditional methods. For example, in October 2023, DELFI Diagnostics Inc., a U.S.-based biotechnology company, introduced FirstLook Lung-a blood-based liquid biopsy test aimed at early lung cancer detection. This test utilizes fragmentomics to identify early-stage lung cancer with high sensitivity and a 99.8% negative predictive value. It is designed to serve as an accessible and convenient initial screening tool for individuals at risk, with the goal of improving early detection rates, boosting screening participation, and helping prioritize imaging resources for those most likely to benefit.
In February 2024, Veracyte Inc., a U.S.-based molecular diagnostics company, acquired C2i Genomics Inc. for an undisclosed amount. Through this acquisition, Veracyte seeks to strengthen its cancer diagnostics portfolio by incorporating advanced whole-genome minimal residual disease (MRD) liquid biopsy technology to improve detection and monitoring across various cancer types. C2i Genomics Inc. is a U.S.-based company specializing in cancer detection and monitoring, including liquid biopsy tests for lung cancer.
Major players in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corp, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., MDxHealth SA, Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation.
North America was the largest region in the lung cancer liquid biopsy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lung cancer liquid biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the lung cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The lung cancer liquid biopsy market consists of revenues earned by entities by providing services such as mutation detection and genomic profiling, treatment monitoring, and early diagnosis and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer liquid biopsy market also includes sales of NGS-based assays, CTC detection devices and others. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Lung Cancer Liquid Biopsy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on lung cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for lung cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lung cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product: Instruments; Sconsumables Kits And Reagents; Software And Services
2) By Technology: Multi Gene-Parallel Analysis (Ngs); Single Gene Analysis (Pcr Microarrays)
3) By Biomarker: Cell-Free Deoxyribonucleic Acid; Circulating Tumor Deoxyribonucleic Acid; Extracellular Vesicles; Circulating Tumor Cells; Other Biomarkers
4) By Clinical Application: Therapy Selection; Treatment Monitoring; Early Cancer Screening; Recurrence Monitoring; Other Applications
5) By End User: Diagnostics And Imaging Centres; Hospitals; Academics And Research Centres; Other End Users
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Lung Cancer Liquid Biopsy Market Characteristics
3. Lung Cancer Liquid Biopsy Market Trends And Strategies
4. Lung Cancer Liquid Biopsy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Lung Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework
5.1. Global Lung Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Lung Cancer Liquid Biopsy Market Growth Rate Analysis
5.4. Global Lung Cancer Liquid Biopsy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Lung Cancer Liquid Biopsy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Lung Cancer Liquid Biopsy Total Addressable Market (TAM)
6. Lung Cancer Liquid Biopsy Market Segmentation
6.1. Global Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Instruments
Sconsumables Kits And Reagents
Software And Services
6.2. Global Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Multi Gene-Parallel Analysis (Ngs)
Single Gene Analysis (Pcr Microarrays)
6.3. Global Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cell-Free Deoxyribonucleic Acid
Circulating Tumor Deoxyribonucleic Acid
Extracellular Vesicles
Circulating Tumor Cells
Other Biomarkers
6.4. Global Lung Cancer Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapy Selection
Treatment Monitoring
Early Cancer Screening
Recurrence Monitoring
Other Applications
6.5. Global Lung Cancer Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diagnostics And Imaging Centres
Hospitals
Academics And Research Centres
Other End Users
6.6. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pcr Instruments
Microarray Instruments
Next-Generation Sequencing (Ngs) Instruments
6.7. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sample Collection Kits
Amplification Reagents
Sequencing Reagents
6.8. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Data Analysis Software
Cloud-Based Services
Bioinformatics Tools
7. Lung Cancer Liquid Biopsy Market Regional And Country Analysis
7.1. Global Lung Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Lung Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Lung Cancer Liquid Biopsy Market
8.1. Asia-Pacific Lung Cancer Liquid Biopsy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Lung Cancer Liquid Biopsy Market
9.1. China Lung Cancer Liquid Biopsy Market Overview
9.2. China Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Lung Cancer Liquid Biopsy Market
10.1. India Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Lung Cancer Liquid Biopsy Market
11.1. Japan Lung Cancer Liquid Biopsy Market Overview
11.2. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Lung Cancer Liquid Biopsy Market
12.1. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Lung Cancer Liquid Biopsy Market
13.1. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Lung Cancer Liquid Biopsy Market
14.1. South Korea Lung Cancer Liquid Biopsy Market Overview
14.2. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Lung Cancer Liquid Biopsy Market
15.1. Western Europe Lung Cancer Liquid Biopsy Market Overview
15.2. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Lung Cancer Liquid Biopsy Market
16.1. UK Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Lung Cancer Liquid Biopsy Market
17.1. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Lung Cancer Liquid Biopsy Market
18.1. France Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Lung Cancer Liquid Biopsy Market
19.1. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Lung Cancer Liquid Biopsy Market
20.1. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Lung Cancer Liquid Biopsy Market
21.1. Eastern Europe Lung Cancer Liquid Biopsy Market Overview
21.2. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Lung Cancer Liquid Biopsy Market
22.1. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Lung Cancer Liquid Biopsy Market
23.1. North America Lung Cancer Liquid Biopsy Market Overview
23.2. North America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Lung Cancer Liquid Biopsy Market
24.1. USA Lung Cancer Liquid Biopsy Market Overview
24.2. USA Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Lung Cancer Liquid Biopsy Market
25.1. Canada Lung Cancer Liquid Biopsy Market Overview
25.2. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Lung Cancer Liquid Biopsy Market
26.1. South America Lung Cancer Liquid Biopsy Market Overview
26.2. South America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Lung Cancer Liquid Biopsy Market
27.1. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Lung Cancer Liquid Biopsy Market
28.1. Middle East Lung Cancer Liquid Biopsy Market Overview
28.2. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Lung Cancer Liquid Biopsy Market
29.1. Africa Lung Cancer Liquid Biopsy Market Overview
29.2. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Lung Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles
30.1. Lung Cancer Liquid Biopsy Market Competitive Landscape
30.2. Lung Cancer Liquid Biopsy Market Company Profiles
30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Biocept Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Eurofins Scientific Overview, Products and Services, Strategy and Financial Analysis
31. Lung Cancer Liquid Biopsy Market Other Major And Innovative Companies
31.1. Illumina Inc.
31.2. Sysmex Corporation
31.3. Bio-Rad Laboratories Inc.
31.4. QIAGEN N.V.
31.5. Exact Sciences Corp
31.6. Natera Inc.
31.7. Myriad Genetics Inc.
31.8. NeoGenomics Laboratories Inc.
31.9. Guardant Health Inc.
31.10. MDxHealth SA
31.11. Exosome Diagnostics Inc.
31.12. Menarini Silicon Biosystems S.p.A.
31.13. Inivata Ltd
31.14. Lucence Diagnostics Pte Ltd
31.15. LungLife AI Inc.
32. Global Lung Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Lung Cancer Liquid Biopsy Market
34. Recent Developments In The Lung Cancer Liquid Biopsy Market
35. Lung Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies
35.1 Lung Cancer Liquid Biopsy Market In 2029 - Countries Offering Most New Opportunities
35.2 Lung Cancer Liquid Biopsy Market In 2029 - Segments Offering Most New Opportunities
35.3 Lung Cancer Liquid Biopsy Market In 2029 - Growth Strategies
